EP2442803A4 - Modulation of systemic exposure to rifaximin - Google Patents

Modulation of systemic exposure to rifaximin

Info

Publication number
EP2442803A4
EP2442803A4 EP10790086A EP10790086A EP2442803A4 EP 2442803 A4 EP2442803 A4 EP 2442803A4 EP 10790086 A EP10790086 A EP 10790086A EP 10790086 A EP10790086 A EP 10790086A EP 2442803 A4 EP2442803 A4 EP 2442803A4
Authority
EP
European Patent Office
Prior art keywords
rifaximin
modulation
systemic exposure
systemic
exposure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10790086A
Other languages
German (de)
French (fr)
Other versions
EP2442803A1 (en
Inventor
William Forbes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Salix Pharmaceuticals Ltd
Original Assignee
Salix Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Salix Pharmaceuticals Ltd filed Critical Salix Pharmaceuticals Ltd
Publication of EP2442803A1 publication Critical patent/EP2442803A1/en
Publication of EP2442803A4 publication Critical patent/EP2442803A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
EP10790086A 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin Withdrawn EP2442803A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18725109P 2009-06-15 2009-06-15
US29769610P 2010-01-22 2010-01-22
PCT/US2010/038742 WO2010148040A1 (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin

Publications (2)

Publication Number Publication Date
EP2442803A1 EP2442803A1 (en) 2012-04-25
EP2442803A4 true EP2442803A4 (en) 2012-11-28

Family

ID=43356731

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10790086A Withdrawn EP2442803A4 (en) 2009-06-15 2010-06-15 Modulation of systemic exposure to rifaximin

Country Status (9)

Country Link
EP (1) EP2442803A4 (en)
KR (1) KR20120030542A (en)
CN (1) CN102625701A (en)
AU (1) AU2010260089B2 (en)
CA (1) CA2765577A1 (en)
MX (1) MX2011013427A (en)
NZ (1) NZ597080A (en)
RU (1) RU2571268C2 (en)
WO (1) WO2010148040A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1698630E (en) 2005-03-03 2014-09-15 Alfa Wassermann Spa New polymorphous forms of rifaximin, processes for their production and use thereof in the medicinal preparations
ITBO20050123A1 (en) 2005-03-07 2005-06-06 Alfa Wassermann Spa GASTRORESISTIC PHARMACEUTICAL FORMULATIONS CONTAINING RIFAXIMINA
WO2021152587A1 (en) 2020-01-30 2021-08-05 Yeda Research And Development Co. Ltd. Treating acute liver disease with tlr-mik inhibitors

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011486A1 (en) * 2007-07-06 2009-01-07 Lupin Ltd. Pharmaceutical compositions of rifaximin
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2011005388A1 (en) * 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2011153327A1 (en) * 2010-06-02 2011-12-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009008005A1 (en) * 2007-07-06 2009-01-15 Lupin Limited Pharmaceutical compositions of rifaximin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2011486A1 (en) * 2007-07-06 2009-01-07 Lupin Ltd. Pharmaceutical compositions of rifaximin
WO2010040020A1 (en) * 2008-10-02 2010-04-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2011005388A1 (en) * 2009-06-02 2011-01-13 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2011153327A1 (en) * 2010-06-02 2011-12-08 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASS N ET AL: "93 RIFAXIMIN IS EFFECTIVE IN MAINTAINING REMISSION IN HEPATIC ENCEPHALOPATHY: RESULTS OF A LARGE, RANDOMIZED, PLACEBO-CONTROLLED TRIAL", JOURNAL OF HEPATOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 50, 1 April 2009 (2009-04-01), pages S39, XP026495706, ISSN: 0168-8278, [retrieved on 20090401], DOI: 10.1016/S0168-8278(09)60095-7 *
NINNI A.: "Il trattamento con rifamicina SV negli epatopazienti non peggiora lo stato di sofferenza preesistente e fa rilevare concentrazioni ematiche piu elevate", CHEMOTHERAPY, 1 January 1963 (1963-01-01), pages 567 - 568, XP055041591, Retrieved from the Internet <URL:http://content.karger.com/ProdukteDB/produkte.asp?Aktion=ShowPDF&ArtikelNr=220193&Ausgabe=245747&ProduktNr=223834&filename=220193.pdf> [retrieved on 20121019] *
See also references of WO2010148040A1 *

Also Published As

Publication number Publication date
RU2012101310A (en) 2013-07-27
WO2010148040A1 (en) 2010-12-23
MX2011013427A (en) 2012-04-20
AU2010260089B2 (en) 2015-05-14
NZ597080A (en) 2014-02-28
EP2442803A1 (en) 2012-04-25
CN102625701A (en) 2012-08-01
KR20120030542A (en) 2012-03-28
RU2571268C2 (en) 2015-12-20
CA2765577A1 (en) 2010-12-23
AU2010260089A1 (en) 2012-01-19

Similar Documents

Publication Publication Date Title
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
IL196456A0 (en) Uderbelly of armord vehicle
PL2340960T3 (en) State of charge range
EP2445343A4 (en) Prodrugs of nh-acidic compounds
PL2430010T3 (en) Oxidation of furfural compounds
EP2394426A4 (en) Improvements to camera for vehicle
IL222900A (en) Forms of rifaximin
SI2510089T1 (en) Synthesis of prazole compounds
EP2438246A4 (en) Aspects of construction
EP2454554A4 (en) Equal-path interferometer
ZA201102604B (en) Alkylcyclohexylethers of dihydrotetraazabenzoazulenes
GB2469158B (en) Base-assisted formation of tin-sucrose adducts
PL2133419T3 (en) Uses of cyanophycin beta-dipeptides
HK1160925A1 (en) Use of athepsin
IL223926A0 (en) Synthesis of cyclopentaquinazolines
EP2442803A4 (en) Modulation of systemic exposure to rifaximin
EP2501803A4 (en) Methods of enhancing pluripotentcy
GB0922023D0 (en) Preparation of n-monofluoroalkyl compounds
SI2504309T1 (en) Synthesis of acetoxyacetaldehyde
EP2331490A4 (en) Preparation of dibutoxymethane
EP2379502A4 (en) Novel forms of eperisone
EP2459540A4 (en) Preparation of fipamezole
TWM372743U (en) Improved structure of Kendama
TWM365675U (en) Improved structure of teapoy
GB0816419D0 (en) Production of hydroelecticity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20121029

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/437 20060101AFI20121023BHEP

Ipc: A61P 1/12 20060101ALI20121023BHEP

Ipc: A61P 1/16 20060101ALI20121023BHEP

Ipc: A61K 31/397 20060101ALI20121023BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1168794

Country of ref document: HK

17Q First examination report despatched

Effective date: 20140521

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20160806

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1168794

Country of ref document: HK